Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
2023년 16개국에서 89,000명 이상의 레녹스 가스토 증후군(LGS) 환자가 발생할 것으로 예상됩니다. 현재 시판되고 있는 LGS 치료제는 모두 저분자 화합물이며, 주로 수용체 작용제 또는 이온 채널 차단제이며, LGS 치료제로 개발 중인 30개 품목 중 1개 품목은 등록 전, 3개 품목은 임상 3상 단계에 있습니다.
LGS 자산을 개발하는 기업이 참여하는 프로젝트 중 인수합병이 아시아태평양, 아프리카, 유럽에서 가장 많았으며, 제휴는 아프리카와 유럽 시장에서 가장 큰 비중을 차지하고 있습니다.
이 보고서는 레녹스 가스토 증후군(LGS) 치료제의 현재와 미래의 경쟁 상황에 대한 데이터 기반 개요를 제공합니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질병 상황
제4장 출시 약제 평가
- 주요 출시 약제
- 작용기서별 개요
- 투여 경로별 개요
- 출시 약제 프로파일과 매출 예측
제5장 가격 설정과 상환 평가
제6장 파이프라인 약제 평가
- 제Ⅲ상 파이프라인 약제
- 개발 단계별 개요
- 분자 유형별 개요
- 작용기서별 개요
- 투여 경로별 개요
- 의약품 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
- 치료 분야 및 적응증 고유의 PTSR 및 LoA
제7장 임상시험 평가
- 역사적 개요
- 단계별 개요
- 상황별 개요
- 진행중 및 계획중인 시험 단계별 개요
- 가상 컴포넌트를 사용한 임상시험
- 지역적 개요
- 지역별 단일국 및 다국적 시험
- 상위 20개 스폰서의 단계별 내역
- 상위 20개 스폰서의 상황별 내역
- 엔드포인트 상황별 개요
- 인종 및 민족별 개요
- 등록 데이터
- 임상시험 사이트 상위 20국
- 세계의 상위 20개 사이트
- 실현 가능성 분석 - 지역적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
- 지역별 합병, 인수, 전략적 제휴
- 최근의 합병, 인수, 전략적 제휴
제9장 상업적 평가
제10장 향후 시장 촉매
제11장 부록
ksm
Abstract
This reports provides a data-driven overview of the current and future competitive landscape in LGS therapeutics.
More than 89,000 total prevalent cases of LGS are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for LGS.
All of the marketed products for LGS are small molecules and are mainly receptor agonists or ion channel blockers.
Out of 30 drugs in development for LGS, one is in pre-registration and three are in Phase III.
Commercial sponsors have led the clinical trials space for LGS over the past 10 years, with Takeda Pharmaceutical sponsoring the highest number of trials overall (15 trials).
In deals involving companies developing LGS assets, acquisition was the most prevalent deal type in Asia Pacific, Africa, and Europe, while partnership took the major chunk of share across African and European markets.
Scope
GlobalData's LGS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the LGS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global LGS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
